BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 18055314)

  • 41. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interim analyses in clinical trials: why do we plan them?
    Fossâ SD; Skovlund E
    J Clin Oncol; 2000 Dec; 18(24):4007-8. PubMed ID: 11118460
    [No Abstract]   [Full Text] [Related]  

  • 44. Preliminary data release for randomized clinical trials of noninferiority: a new proposal.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    J Clin Oncol; 2005 Aug; 23(24):5831-6. PubMed ID: 16027441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
    Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
    Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. On changing a long-term clinical trial midstream.
    Wittes J
    Stat Med; 2002 Oct; 21(19):2789-95. PubMed ID: 12325094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sample size tables for exact single-stage phase II designs.
    A'Hern RP
    Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A mixed approach for proving non-inferiority in clinical trials with binary endpoints.
    Rousson V; Seifert B
    Biom J; 2008 Apr; 50(2):190-204. PubMed ID: 18311852
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 53. Discussion of paper by Korn and Freidlin.
    Wittes J
    Am J Bioeth; 2011 Mar; 11(3):13-4. PubMed ID: 21400376
    [No Abstract]   [Full Text] [Related]  

  • 54. Factorial dose-response studies using frequency and magnitude of dose.
    Hafner KB; Ruberg SJ
    J Biopharm Stat; 1996 Jul; 6(3):253-62. PubMed ID: 8854230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.
    Howard G; Coffey CS; Cutter GR
    Stroke; 2005 Jul; 36(7):1622-3. PubMed ID: 15947275
    [No Abstract]   [Full Text] [Related]  

  • 56. A model for the interim analysis process: a case study.
    Delgado-Herrera L; Anbar D
    Control Clin Trials; 2003 Feb; 24(1):51-65. PubMed ID: 12559642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How a sequential design would have affected the GAIN International Study of gavestinel in stroke.
    Bolland K; Weeks A; Whitehead J; Lees KR;
    Cerebrovasc Dis; 2004; 17(2-3):111-7. PubMed ID: 14707409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized, controlled clinical trials in sepsis: has methodological quality improved over time?
    Graf J; Doig GS; Cook DJ; Vincent JL; Sibbald WJ
    Crit Care Med; 2002 Feb; 30(2):461-72. PubMed ID: 11889331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.
    Bird SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11744570
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.